All In Biotech

Drug Trial Radar · NCT02496663

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

A Phase I Trial of Osimertinib (AZD9291) and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

May 11, 2016

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
NIH
First posted
Jul 14, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the safety, side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back after a period of improvement (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be safe, tolerable in treating patients with EGFR-mutant non-small cell lung cancer.

Conditions

  • Metastatic Lung Non-Small Cell Carcinoma
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT scan

  • Echocardiography TestProcedure

    Undergo ECHO

  • Magnetic Resonance ElastographyProcedure

    Undergo MRI

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • NecitumumabBiological

    Given IV

  • OsimertinibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) of necitumumab combined with osimertinibTime frame: 21 days
  2. Incidence of toxicityTime frame: Up to 1 year

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • UCHealth University of Colorado Hospital

    Aurora, Colorado

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Duke Cancer Center Cary

    Cary, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.